Navigation Links
Essential Pharmaceuticals Acquires Exclusive Worldwide Rights to Family of Cell Media Products from Lifeblood Medical
Date:10/27/2010

NEWTOWN, Pa., Oct. 27 /PRNewswire/ -- Essential Pharmaceuticals, LLC, a private company dedicated to providing specialty reagents and solutions to the life sciences market, announced today that the Company will commence sales and distribution of three distinct animal-component-free products: serum replacement, cryopreservation and clinical pathology media, formerly sold under the LiforCell® name:

  • Cell-Ess™ Serum Replacement cell culture medium,
  • Cryo-Ess™ cryopreservation medium, and
  • Clin-Ess™ transportation medium.

"The quality and consistency of Cell-Ess, Cryo-Ess and Clin-Ess gives scientists the confidence to conduct their research without testing each new serum lot purchased, resulting in improved laboratory efficiency and valuable cost savings," said Allan Weber, chief executive officer of Essential Pharmaceuticals.  "Moreover, we believe that the characteristics of these media products offer important clinical benefits, making Cell-Ess the ideal choice for use in the cutting edge areas of stem cell, cancer and vaccine research, and Clin-Ess in the preservation of limbs and organs for surgical applications."  

The Cell-Ess, Cryo-Ess and Clin-Ess family offers researchers the advantage of superior performance compared to fetal bovine serum. They are free of all animal components and dimethyl sulfoxide (DSMO), do not crystallize or form ice during the thawing process, resulting in less DNA and RNA degradation and fewer artifacts than those preserved using conventional methods. Further, they have demonstrated synthetic reproducibility with no lot-to-lot variability.  

Essential Pharmaceuticals acquired exclusive worldwide rights to these media products, originally the LiforCell® family of products, from Lifeblood Medical, Inc. These cell culture and cryopreservation products have been re-branded to correlate to their specific research and clinical applications.  

"Essential Pharmaceuticals is known for its outstanding customer support in highly specialized fields," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical. "That, along with the superior advantages of these cell culture and cryopreservation media, will generate increased growth and market penetration of the Lifeblood technology."

About Essential Pharmaceuticals

Essential Pharmaceuticals LLC, a key company in the organ transplant arena, provides Custodiol® HTK organ preservation solution to the transplant medical community.  Essential is well-known for excelling in highly specialized medical areas through a combination of outstanding customer support coupled with customized distribution systems and ongoing research projects to further knowledge in the field of organ preservation.  Essential plans on bringing this proven model to support medical researchers and further their projects, improving future medical discoveries globally.

For additional information about Essential Pharmaceuticals new family of cell media products, or any other Essential product, please visit our website at www.essentialpharma.com, e-mail to info@essentialpharma.com or call 1-267-757-0112.

*CUSTODIOL® HTK is a registered trademark of Dr. Franz Kohler Chemie GmbH, Alsbach-Hahnlein, Germany.

*LiforCell® is a registered trademark of Lifeblood Medical, Inc.


'/>"/>
SOURCE Essential Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
2. Laerdal Introduces SimMan Essential
3. Health Outcomes Data Essential to Biopharmaceutical Sales Process
4. Creative Alliances with Nontraditional Players Increasingly Essential for Survival in Pharmaceutical Industry, New Ernst & Young Report Finds
5. Weekly Digests Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 Swine Flu Outbreak
6. Essentialis to Submit SPA for Hypertriglyceridemia
7. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
8. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
9. Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
10. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
11. Teva Pharmaceuticals and the Philadelphia Eagles Award Four Grants to Greater Philadelphia Area Service Organizations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):